本品是由Vestar和Lyphomed制药公司联合开发的两性霉素B脂质体制剂。1989年第3季度开始在欧洲进行Ⅲ期临床试验。可望1992年在美国批准上市。临床试验表明,对100名患有严重的免疫缺陷病人,只给予两性霉素B常规剂量的1/3或1/4(即3～4mg/kg相当于lmg/kg)的两性霉素B脂质体后,对其中50%患有真菌感染病人有效,对50%患有肾功能疾病的病人33%恢复至正常。 This product is amphotericin B liposomal formulation developed jointly by Vestar and Lyphomed Pharmaceuticals. The third quarter of 1989 began in Europe Ⅲ phase clinical trials. May be approved in the United States in 1992 listing. Clinical trials have shown that for 100 patients with severe immunodeficiency, amphotericin B lipids are only given at 1/3 or 1/4 of the usual dose of amphotericin B (ie 3-4 mg / kg equivalent to 1 mg / kg) After plastids, 50% of patients with fungal infections were effective, and 50% of patients with renal dysfunction returned to normal.